Sublicensing Revenues. (a) [***] Sublicense. Myriad shall pay to Maxim [***] of all Sublicensing Revenues received by Myriad or any of its Affiliates with respect to sublicenses of the right to develop, make, have made, use, distribute for sale, promote, market, offer for sale, sell, have sold, import or export Products [***].
(b) [***] Sublicense. If Myriad grants to a Sublicensee the right to develop, make, have made, use, distribute for sale, promote, market, offer for sale, sell, have sold, import or export Products [***], Myriad shall pay to Maxim milestone payments based on the achievement of any milestone set forth in Section 6.3 above by any such Sublicensee. Myriad shall also pay to Maxim royalties on the Net Sales of Products by all such Sublicensees [***] based on the royalty rate set forth in Section 6.4 above.
Sublicensing Revenues. If Reneo grants to a Third Party a sublicense under any of the vTv Technology to Develop, Manufacture or Commercialize a Licensed Product in the Territory, beyond the mere right to purchase such Licensed Product from or to provide services on behalf of Reneo and its Affiliates, Reneo would pay to vTv: (a) the royalties payable pursuant to Section 3.5 on Net Sales of Licensed Products by such Sublicensee; and (b) a percentage of Sublicensing Revenues received by Reneo or its Affiliates from such Sublicensee in consideration for such sublicense as follows: (i) [***], if such sublicense is first entered into prior to [***]; and (ii) [***], if such sublicense is first entered into on or after [***]. Notwithstanding the foregoing, in the event that Reneo or its Affiliate receives Sublicensing Revenues for the achievement of a milestone event set forth in Section 3.3 or 3.4, Reneo shall pay vTv the greater of (A) [***]; or (B) [***], but not both. For the purposes of this Section 3.6, “Sublicensing Revenues” means [***] received by Reneo or any of its Affiliates from a Sublicensee in consideration for a sublicense under any of the vTv Technology to Develop, Manufacture or Commercialize a Licensed Product, but excludes [***].
Sublicensing Revenues. The term “Sublicensing Revenues” shall mean [***].
Sublicensing Revenues. If Lumena sublicenses Commercialization rights to any Third Party, Lumena would pay to Sanofi, (i) the Royalties set forth in Section 3.5(a), and (ii) in lieu of the payments under Sections 3.3 and 3.4, a percentage of any and all licensing revenues received by Lumena or its Affiliates from such Third Party in consideration for such sublicense, on a Licensed Product-by-Licensed Product basis, as follows: (a) [...***...], if such sublicense is entered into prior to [...***...]; and (b) [...***...], if such sublicense is entered into after [...***...], provided however, that in the event that the total payments made by Lumena under subparagraph (ii) above are less than the payments that would have been made by Lumena under Sections 3.3 and 3.4 for achievement of the milestone events in Sections 3.3 and 3.4 that are actually achieved, then Lumena will pay Sanofi [...***...
Sublicensing Revenues. In the event of any sublicense to the rights granted pursuant to this agreement, licensee shall pay Licensor 2% of sublicensing revenues collected by Licensee.
Sublicensing Revenues. The term “Sublicensing Revenues” shall mean all amounts actually received by Licensee and its Affiliates from any Sublicensee or Commercial Partner, in consideration of the grant by Licensee or its Affiliate of a sublicense or other distribution or marketing rights under the Licensed Technology. Without limiting the generality of the foregoing, Sublicensing Revenues shall include, without limitation, all up-front fees, license fees, milestone payments, technology access fees, premiums above the fair market value on sales of debt or equity securities of Licensee or of an Affiliate, annual maintenance fees, and any other payments with respect to the grant of a sublicense or distribution or marketing rights. Sublicensing Revenues include amounts received from a Sublicensee or Commercial Partner under the terms of the agreement in which the sublicense or other distribution or marketing rights are granted and under the terms of other agreements entered into between Licensee or its Affiliate and the Sublicensee or Commercial Partner as part of the same transaction as the agreement that includes the grant of the sublicense or other distribution or marketing rights. However, Sublicensing Revenues shall exclude: (i) […***…]; (ii) […***…]; (iii) […***…]; and (iv) […***…] […***…].
Sublicensing Revenues. If within twenty-four (24) months after the License Agreement Effective Date CureVac grants a sublicense to a Third Party under this License Agreement for the development and commercialization of Licensed Products, then CureVac will pay to Arcturus […***…] of all Sublicense Income actually received by CureVac, to the extent the Sublicense Income exceeds the Option Exercise Fee paid by CureVac under the Development and Option Agreement to exercise the Option for this License Agreement and the Milestone Payments paid by CureVac under this License Agreement. The payments will be made within […***…] days after receipt by CureVac from the Third Party. For purposes of clarity, if CureVac grants a sublicense to Third Parties later than […***…] months after the License Agreement Effective Date, CureVac will not owe any Sublicensing Income to Arcturus.
Sublicensing Revenues. In addition to the payments, fees and royalties described elsewhere in this Agreement, Intrexon shall pay CONKWEST [***] of all Sublicensing Revenues, due and payable within ten (10) days after receipt by Intrexon of such Sublicensing Revenues.
Sublicensing Revenues. In the event that Servier sublicenses its rights under this Agreement to a Third Party to Commercialize the Initial Product and any Additional Anti-PD-1 Products in countries other than the United States, Servier will be subject to the payment obligations set forth in Section 8.2, Section 8.3 and Section 8.4. In the event Servier sublicenses its rights under this Agreement for the Initial Product or any Additional Anti-PD-1 Products to a Third Party to Commercialize such products in the United States (the “US Sublicense”), then, in lieu of the payment obligations set forth in Section 8.2, Section 8.3 and Section 8.4, Xxxxxx shall pay Sorrento as follows:
8.8.1 If such US Sublicense is entered into before Phase 1 Data (as defined below) is generated, Servier will pay Sorrento * percent (*%) of the Sublicensing Revenues, if and when received by Servier in accordance with the terms set forth in the US Sublicense; and
8.8.2 If such US Sublicense is entered into with no additional clinical data other than the Data arising out of the Phase 1 Clinical Trial of the Initial Product in * (the “Phase 1 Data”), Servier will pay Sorrento * percent (*%) of the Sublicensing Revenues, if [*] Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portion. and when received by Servier in accordance with the terms set forth in the US Sublicense
Sublicensing Revenues. On each Sublicense of any Licensed Product, Licensee shall pay to Licensor a percentage of Sublicensing Revenue received by Licensee from the Sublicensee depending on the date on which the applicable Sublicense is entered into, as follows:
